Fierce Biotech Mix Logo.png Fierce Biotech Mix Logo.png
Webinar

Rethinking Drug Commercialization: Navigating a Shifting Biotech Investment Landscape

ET
60 Minutes

The biotech dealmaking landscape is changing—deals are happening later in development, and securing capital is tougher than ever. For biotech companies, especially those developing precision and rare disease therapies, this creates unexpected commercialization challenges with limited resources and expertise. Join this webinar for a deep dive into today’s biotech investment climate and practical strategies to navigate commercialization when pharma partnerships are delayed or uncertain.

In this webinar, you'll learn:

  • How shifting biotech M&A trends are impacting commercialization
  • Key commercialization challenges for precision and rare disease therapies
  • Ways to bridge the funding gap and de-risk commercialization
  • A data-driven approach to launch success
  • And more

Speakers

Diaceutics

Susanne Munksted

Chief Precision Medicine Officer
Diaceutics

Susanne brings a wealth of experience to her role in leading a global team of precision medicine industry experts dedicated to enhancing the testing ecosystem to help patients capitalize on new breakthrough personalized medications. Susanne's journey in molecular pathology has been marked by notable achievements, including spearheading several global launches of companion diagnostic products. As a leading author of the Practice Gaps Study, Susanne played a pivotal role in identifying 7 key clinical Practice Gaps contributing to patient leakage, and her impactful contributions to the field have earned her a well-deserved place among the PharmaVoice 100 list of transformational leaders in life sciences.

Register here!

Already registered? Click here to login.
Date/Time:
ET